Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T11:46:54.478Z Has data issue: false hasContentIssue false
  • English
  • Français

Anticonvulsant drugs and mental symptoms: a review

Published online by Cambridge University Press:  09 July 2009

M. R. Trimble  and
E. H. Reynolds
M. R. Trimble
Affiliation:
Reprint requests to: Department of Neurology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF
E. H. Reynolds
Affiliation:
Reprint requests to: Department of Neurology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 6 , Issue 2 , May 1976 , pp. 169 - 178
Copyright
Copyright © Cambridge University Press 1976

References

REFERENCES

Barnes, M. R. & Fetterman, J. N. (1938). Mentality of dispensary epileptic patients. Archives of Neurology and Psychiatry 40, 903–910.CrossRefGoogle Scholar
Betts, T. A. (1974). A follow-up study of a cohort of patients with epilepsy admitted to psychiatric care in an English city. In Harris, P. & Maudsley, C. (eds), Epilepsy; Proceedings of the Hans Berger Centenary Symposium, pp. 326–336. Churchill Livingstone: Edinburgh.Google Scholar
Booker, H. E., Matthews, C. G. & Slaby, A. (1967). Effects of diphenylhydantoin on selected physiological-psychological measures in normal adults. Neurology 17, 949–951.CrossRefGoogle Scholar
Browne, T. R., Dreifuss, F. E., Dyken, P. R., Goode, D. J., Penry, J. K., Porter, R. J., White, B. G. & White, P. T. (1975). Ethosuximide (zarontin) in the treatment of absence (petit mal) seizures. Neurology 25, 515–525.CrossRefGoogle ScholarPubMed
Buchthal, F. & Svensmark, O. (1971). Serum concentrations of diphenylhydantoin and phenobarbital and their relation to therapeutic and toxic effects. Psychiatria, Neurologia et Neurochirurgia 74, 117–136.Google ScholarPubMed
Chadwick, D., Jenner, P. & Reynolds, E. H. (1975). Amines, anticonvulsants and epilepsy. Lancet i, 473–476.CrossRefGoogle Scholar
Chaudhry, M. R. & Pond, D. A. (1961). Mental deterioration in epileptic children. Journal of Neurology, Neurosurgery and Psychiatry 24, 213–219.CrossRefGoogle ScholarPubMed
Dalby, M. A. (1975). Carbamazepine: behavioural effects. In Penry, J. K. (ed.), Complex Partial Seizures and their Treatment, pp. 331–344. Raven Press: New York.Google Scholar
Davison, K. & Bagley, C. (1969). Schizophrenia-like psychoses associated with organic disorders of the nervous system. In Current Problems in Psychiatry. British Journal of Psychiatry, Special Publication Number 4.Google Scholar
Finkelman, I. & Arieff, A. J. (1942). Untoward effects of phenytoin sodium in epilepsy. Journal of the American Medical Association 118, 1209–1212.CrossRefGoogle Scholar
Fox, J. T. (1924). Response of epileptic children to mental and educational tests. British Journal of Medical Psychology 4, 235–248.CrossRefGoogle Scholar
Frantzen, E., Hansen, J. M., Hansen, O. E. & Kristensen, M. (1967). Phenytoin (dilantin) intoxication. Acta Neurologica Scandinavica 43, 440–446.CrossRefGoogle ScholarPubMed
Glaser, G. H. (1972). Diphenylhydantoin toxicity. In Woodbury, D. M., Penry, J. K. & Schmidt, R. P. (eds), Antiepileptic Drugs, pp. 219–226. Raven Press: New York.Google Scholar
Goode, D. J., Penry, J. K. & Dreifuss, F. E. (1970). Effect of paroxysmal spike-wave on continuous visual motor performance. Epilepsia 11, 241–254.CrossRefGoogle ScholarPubMed
Gowers, W. R. (1885). Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms and Treatment. William Wood: London.Google Scholar
Grinker, R. R. (1929). The proper use of phenobarbital in the treatment of the epilepsies. Journal of the American Medical Association 93, 1218–1219.CrossRefGoogle Scholar
Guerrant, J., Anderson, W. W., Fischer, A., Weinstein, M. R., Jaros, R. M. & Deskins, A. (1962). Personality in Epilepsy. Thomas: Springfield.CrossRefGoogle Scholar
Guey, J., Charles, C., Coquery, C., Roger, J. & Soulayrol, R. (1967). Study of psychological effects of ethosuccimide (zarontin) on 25 children suffering from petit mal epilepsy. Epilepsia 8, 129–141.CrossRefGoogle Scholar
Haerer, A. F. & Grace, J. B. (1969). Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45, 18–31.CrossRefGoogle ScholarPubMed
Holdsworth, L. & Whitmore, K. (1974). A study of children with epilepsy attending ordinary schools. Developmental Medicine and Child Neurology 16, 746–758.CrossRefGoogle ScholarPubMed
Husby, J. (1963). Delayed toxicity and serum concentrations of phenytoin. Danish Medical Bulletin 10, 236–239.Google ScholarPubMed
Hutt, S. J., Jackson, P. M., Belsham, A. B. & Higgins, G. (1968). Perceptual-motor behaviour in relation to blood phenobarbitone level. Developmental Medicine and Child Neurology 10, 626–632.CrossRefGoogle ScholarPubMed
Ideström, C. M., Schalling, D., Carlquist, U. & Sjöquist, F. (1972). Behavioural and psychophysiological studies: acute effects of diphenylhydantoin in relation to plasma levels. Psychological Medicine 2, 111–120.CrossRefGoogle ScholarPubMed
Kerfriden, P. (1970). Effets psychiques de favorables des médications anticomitiales. Revue de Neuropsychiatrie Infantile 18, 605–609.Google Scholar
Kooiker, J. C. & Sumi, S. M. (1974). Movement disorder as a manifestation of diphenylhydantoin intoxication. Neurology 24, 68–71.CrossRefGoogle ScholarPubMed
Kutt, H., Winters, W., Kokenger, R. & McDowell, F. (1964). Diphenylhydantoin metabolism, blood levels and toxicity. Archives of Neurology 11, 642–648.CrossRefGoogle ScholarPubMed
Landolt, H. (1958). Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In de Haas, A. M. Lorentz (ed.). Lectures on Epilepsy, pp. 91–133. Elsevier: Amsterdam.Google Scholar
Lennox, W. G. (1942). Brain injury, drugs and environment as causes of mental decay in epilepsy. American Journal of Psychiatry 99, 174–180.CrossRefGoogle Scholar
Lennox, W. G. & Lennox, M. A. (1960). Epilepsy and Related Disorders. Little, Brown: Boston.Google Scholar
Logan, W. J. & Freeman, J. M. (1969). Pseudodegenerative disease due to diphenylhydantoin intoxication. Archives of Neurology 21, 631–637.CrossRefGoogle ScholarPubMed
Loveland, N., Smith, B. & Forster, F. M. (1957). Mental and emotional changes in epileptic patients on continuous anticonvulsant medication. Neurology 7, 856–865.CrossRefGoogle ScholarPubMed
McLellan, D. L. & Swash, M. (1974). Choreoathetosis and encephalopathy induced by phenytoin. British Medical Journal ii, 204–205.CrossRefGoogle Scholar
Meduna, L. (1937). Die Konvulsionstherapie der Schizophrenie. Marhold: Halle.Google Scholar
Merritt, H. H. (1955). A Textbook of Neurology. Lea and Febiger: Philadelphia.Google Scholar
Ounsted, C. (1955). The hyperkinetic syndrome in epileptic children. Lancet ii, 303–311.CrossRefGoogle Scholar
Patel, H. & Crichton, J. U. (1968). The neurologic hazards of diphenylhydantoin in childhood. Journal of Pediatrics 73, 676–684.CrossRefGoogle ScholarPubMed
Perlo, V. P. & Schwab, R. S. (1969). Unrecognized dilantin intoxication. In Locke, S. (ed.), Modern Neurology, pp. 589–597. Little, Brown: Boston.Google Scholar
Pollack, M. (1970). Chlorpromazine and CNS changes in man. In Smith, W. L. & Ulett, G. A. (eds), Drugs and Cerebral Function. Thomas: Springfield.Google Scholar
Prensky, A. L., De Vivo, D. C. & Palkes, H. (1971). Severe bradykinesia as a manifestation of toxicity to antiepileptic medications. Journal of Pediatrics 78, 700–704.CrossRefGoogle ScholarPubMed
Rawson, M. D. (1968). Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurology 18, 1009–1011.CrossRefGoogle ScholarPubMed
Reynolds, E. H. (1968). Epilepsy and schizophrenia: relationship and biochemistry. Lancet i, 398–401.CrossRefGoogle Scholar
Reynolds, E. H. (1970). Iatrogenic disorders in epilepsy. In Williams, D. (ed.), Modern Trends in Neurology, no. 5, pp. 271–286. Butterworths: London.Google Scholar
Reynolds, E. H. & Travers, R. D. (1974). Serum anticonvulsant concentrations in epileptic patients with mental symptoms. British Journal of Psychiatry 124, 440–445.CrossRefGoogle ScholarPubMed
Reynolds, E. H. (1975 a). Chronic antiepileptic toxicity: a review. Epilepsia 16, 319–352.CrossRefGoogle ScholarPubMed
Reynolds, E. H. (1975 b). Carbamazepine neurotoxicity. In Penry, J. K. & Daly, D. (eds), Complex Partial Seizures and their Treatment, pp. 345–353. Raven Press: New York.Google Scholar
Reynolds, E. H., Chadwick, D., Jenner, P. & Chanarin, I. (1975). Folate and monoamine metabolism in epilepsy. Journal of Neurological Sciences 26, 605–615.CrossRefGoogle ScholarPubMed
Roger, J., Grangeon, H., Guey, J. & Lob, H. (1968). Incidences psychiatriques et physiologiques du traitement par l'éthosuccimide chez les épileptiques. L'encéphale 5, 407–438.Google Scholar
Roseman, E. (1961). Dilantin toxicity. Neurology 11, 912–921.CrossRefGoogle ScholarPubMed
Rosen, J. A. (1968). Dilantin dementia. Transactions of the American Neurological Association 93, 273.Google ScholarPubMed
Royo, D. & Martin, F. (1959). Standardized psychometrical tests applied to the analysis of the effect of anticonvulsant medication on the intellectual proficiency of young epileptics. Epilepsia 1, 189–207.CrossRefGoogle Scholar
Simopoulos, A. M., Pinto, A., Uhlenhuth, E. H., McGee, J. J. & De Rosa, E. R. (1974). Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. Archives of General Psychiatry 30, 106–111.CrossRefGoogle ScholarPubMed
Slater, E., Beard, A. W. & Glithero, E. (1963). The schizophrenia-like psychoses of epilepsy. British Journal of Psychiatry 109, 95–150.CrossRefGoogle Scholar
Smith, W. L., Philipus, M. J. & Guard, H. L. (1968). Psychometric study of children with learning problems and 14–16 positive spike EEG patterns, treated with ethosuccimide (zarontin) and placebo. Archives of Diseases of Childhood 43, 616–619.CrossRefGoogle Scholar
Somerfeld-Ziskind, E. & Ziskind, E. (1940). Effect of phenobarbital on the mentality of epileptic patients, Archives of Neurology and Psychiatry 43, 70–79.CrossRefGoogle Scholar
Soulayrol, R. & Roger, J. (1970). Effets psychiatriques défavorables des médications anti-épileptiques. Revue de Neuropsychiatrie infantile 18, 591–598.Google Scholar
Temkin, O. (1971). The Falling Sickness. Johns Hopkins: Baltimore.Google Scholar
Tehicaloff, M. & Gaillard, F. (1970). Quelques effets indésirables des médicaments anti-épileptiques sur les rendements intellectuels. Revue de Neuropsychiatrie infantile 18, 599–602.Google Scholar
Turner, W. J. (1967). Therapeutic use of diphenylhydantoin in neuroses. International Journal of Neuropsychiatry 3, 94–105.Google Scholar
Weiss, C. F., Heffelfinger, J. C. & Buchanan, R. A. (1969). Serial dilantin levels in mentally retarded children. American Journal of Mental Deficiency 73, 826–830.Google ScholarPubMed
Wapner, I., Thurston, D. L. & Holowach, J. (1962). Phenobarbital: its effect on learning in epileptic children. Journal of the American Medical Association 182, 937.Google ScholarPubMed
Wolf, P. (1973). Zur Pathophysiologic epileptischer Psychosen. In Penin, H. (ed), Psychische Störungen bei Epilepsie, pp. 51–65. F. K. Schattauer Verlag: Stuttgart.Google Scholar
Woodbury, D. M., Penry, J. K. & Schmidt, R. P. (eds), (1972). Antiepileptic Drugs. Raven Press: New YorkGoogle Scholar